Key result
Mosapride administration (3 mg/kg twice daily) in conscious dogs significantly increased heart rate by up to 34.4% and shortened QT interval, but did not cause fatal arrhythmogenic effects or abnormal QTc prolongation.
Answers are grounded in this paper and cite their sources.
Supports short-term cardiac safety of mosapride in dogs; leaves open human QT effects.
Mosapride stimulated dietary motility was introduced because of the arrhythmogenic effect of cisapride. Cisapride, 5-HT receptor agonist, induces prolongation of QT interval. Additionally, this condition can raise the possibility of acute, "malignant" arrhythmias such as torsade de pointes. It is hard to find any reports about effects of mosapride on cardiac parameters in dogs. By confirming electrocardiogram (ECG) parameters, the surface extremity leads ECG that was obtained from the four-limb electrodes and which was recorded by an ECG recorder after administration of mosapride 3 mg/kg PO b.i.d, and mosapride 3 mg/kg with itraconazole 5 mg/kg PO b.i.d, respectively. QT interval was shortened on the days of 3, 5, and post-day 1 in both mosapride 3 mg/kg administrated group and mosapride with itraconazole group. Heart rate increased significantly. QTc was slightly prolonged in mosapride administration group and mosapride with itraconazole group. However, all dogs of QTc were in normal variation (150~250 msec). Besides, the dogs showed no side effects reported in human medicine during the administration with these drugs. Although mosapride can increase the heart rate, this study suggest that mosapride may be useful for the dogs with disorders of gastrointestinal motility because of no fatal arrhythmogenic effect inspite of administration with itraconazole in dogs.
No takes yet. Share an insight, caveat, or question.
Chae et al. (2012) studied Healthy (n=6). Mosapride citrate vs. Mosapride 3 mg/kg with itraconazole 5 mg/kg PO b.i.d was evaluated on QT interval and QTc. Mosapride administration (3 mg/kg twice daily) in conscious dogs significantly increased heart rate by up to 34.4% and shortened QT interval, but did not cause fatal arrhythmogenic effects or abnormal QTc prolongation.
Synapse has enriched 10 related papers. Consider them for comparative context: